Acquire Develop Out-License


Engaging with our industry and partners

  • News
  • Communications

Ellipses announces significant expansion of the Scientific Affairs Group

31 March 2023

Maximizing KOL input to increase the success rate of Oncology R&D

21 March 2023

FDA has granted Orphan Drug Designation to EP0042

14 March 2023

Ellipses Accelerates Cancer Treatment R&D with ‘Unique’ Business Model

13 February 2023

EP0042 FDA IND Approval

1 February 2023

Preliminary results of an ongoing Phase I/IIa first in human study

18 January 2023

Striving to improve treatment options for Acute Myeloid Leukaemia

21 December 2022

First patient dosed with EP0031

14 December 2022

Preliminary data from the phase 1/2 trial of EP0042 presented at ASH

12 December

Poster presentation of vosilasarm (EP0062) at SABCS

5 December 2022

Ellipses Brand Assets

Ellipses Brochure

Ellipses Business Development Brochure

Ellipses Scientific Affairs Group Brochure

Ellipses Scientific Affairs Group Animation

Professor Sir Christopher Evans OBE

Dr Rajan Jethwa

For all media enquiries, please get in touch

Contact us